UAB Nasal Spray COVID Vaccine Showing Early Success in Animal Tests
Preclinical studies of a COVID-19 vaccine candidate at UAB show results that distinguish it from other vaccine candidates that also are in the advanced stages of clinical development, Maryland-based Altimmune announced Tuesday. AdCOVID is a single dose, intranasal spray. In animal models at UAB, it’s use resulted in a potent T-cell response at the mucus layer of the lungs, including killer CD8+ T-cells, which can recognize and kill virally infected cells. Recent reports have suggested the importance of T-cell responses for long-term protection from COVID-19. Read more.